Compare CLNN & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLNN | CSBR |
|---|---|---|
| Founded | 2012 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.6M | 98.5M |
| IPO Year | N/A | 1986 |
| Metric | CLNN | CSBR |
|---|---|---|
| Price | $3.98 | $6.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $32.67 | $12.00 |
| AVG Volume (30 Days) | ★ 124.8K | 5.1K |
| Earning Date | 03-23-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.17 |
| Revenue | $214,000.00 | ★ $58,424,000.00 |
| Revenue This Year | N/A | $4.84 |
| Revenue Next Year | $82.05 | $11.51 |
| P/E Ratio | ★ N/A | $37.71 |
| Revenue Growth | N/A | ★ 9.06 |
| 52 Week Low | $2.28 | $5.59 |
| 52 Week High | $13.50 | $11.98 |
| Indicator | CLNN | CSBR |
|---|---|---|
| Relative Strength Index (RSI) | 31.85 | 48.56 |
| Support Level | $3.88 | $6.58 |
| Resistance Level | $4.50 | $7.71 |
| Average True Range (ATR) | 0.42 | 0.32 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 5.16 | 30.07 |
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.